On Thursday, Shares of Xerox Corporation (NYSE:XRX), lost -0.29% to $10.24, hitting its lowest level.
Nearly three-quarters of small and medium-sized businesses (SMBs) do not have a managed print service (MPS) in place - a substantial opportunity for channel partners to assist clients reduce cost by up to 30 percent annually and improve predictability while generating new, recurring revenue for their business.
Xerox (XRX) has unveiled four new tools within its Xerox Partner Print Services (XPPS) offering to assist partners capitalize on the market opportunity – whether they are selling MPS for the first time or building on an established program. Channel partners can take advantage of Xerox’s three-stage MPS strategy – assess and optimize, secure and integrate, and automate and simplify – to deliver valuable solutions that address their clients’ evolving needs.
Xerox Corporation provides business process and document administration solutions worldwide. The company’s Services segment offers various business process outsourcing services, such as customer care, transaction processing, human resources, communication and marketing, and consulting and analytics services, in addition to finance, accounting, and procurement services.
Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA), inclined 2.36% to $62.13, during its last trading session.
Teva Pharmaceutical Industries Limited, declared the launch of generic Axert® (almotriptan malate) tablets, 6.25 mg and 12.5 mg, in the United States. Teva was the first applicant to submit an Abbreviated New Drug Application (ANDA) for almotriptan malate tablets containing a Paragraph IV patent certification.
The ANDA for almotriptan malate tablets presented by Teva to the US Food and Drug Administration on December 7, 2005, was the first ANDA presented by a generic company containing a Paragraph IV certification for Janssen Pharmaceuticals Axert®. Teva is the first applicant to receive approval and will have a period of market exclusivity until the pediatric exclusivity associated with the only patent for Axert® expires on November 7, 2015.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines.
Finally, Kite Realty Group Trust (NYSE:KRG), ended its last trade flat, and closed at $25.50.
Kite Realty Group Trust, declared that it has upsized its existing Unsecured Term Loan Credit Facility from $230 million to $400 million. The Company exercised an existing accordion option feature to enhance the amount by $170 million.
“We continue to execute on our strategy of maintaining our investment grade quality balance sheet,” said Dan Sink, the Company’s Executive Vice President and Chief Financial Officer. “Expanding our Unsecured Term Loan Credit Agreement enhances our liquidity position and improves our financial flexibility.”
Kite Realty Group Trust is a publicly owned real estate investment trust. The firm invests in real estate markets of the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
